Skip to main content

Table 2 Mouse survival time

From: Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer

Model

Treatment modality

Survival

Median survival time(d)

P value

Lifespan (%)

RKO

131I-Atezolizumab (11.1 MBq)

29

0.326

7.4

131I-Atezolizumab (37 MBq)

34

0.027

25.92

Normal Control

27

–

–

HCT8

131I-Atezolizumab (37 MBq)

42

0.290

10.52

Normal Control

38

–

–

  1. P values were estimated between the experimental and normal control groups by log-rank test, P < 0.05 indicated significance
  2. Percentage increase in lifespan was expressed as (the median survival time of treated/the median survival time of control mice-1) × 100%